Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.6K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.6K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.2K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

967
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
967
Schizophrenia01:17

Schizophrenia

1.8K
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

The Future of <i>DSM</i>: Response to Letters.

The American journal of psychiatry·2026
Same author

Distinct Connectivity Signatures of Hallucinatory Experiences and Neuromelanin Signal in Adolescents.

medRxiv : the preprint server for health sciences·2026
Same author

The Future of <i>DSM</i>: Role of Candidate Biomarkers and Biological Factors.

The American journal of psychiatry·2026
Same author

Initial Strategy for the Future of <i>DSM</i>.

The American journal of psychiatry·2026
Same author

The Future of <i>DSM</i>: A Report From the Structure and Dimensions Subcommittee.

The American journal of psychiatry·2026

Related Experiment Video

Updated: Apr 20, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

5.0K

Schizophrenia: overview and dopamine dysfunction.

Anissa Abi-Dargham1

  • 1From the Division of Translational Imaging, Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York.

The Journal of Clinical Psychiatry
|December 4, 2014
PubMed
Summary
This summary is machine-generated.

Schizophrenia affects millions globally, with most patients relapsing despite initial treatment. Current antipsychotics manage positive symptoms but not negative or cognitive aspects, highlighting the need for comprehensive therapies.

More Related Videos

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.1K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

5.0K
Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.1K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a chronic illness impacting 24 million worldwide.
  • While initial antipsychotic treatment is effective for positive symptoms, long-term recovery is poor, with high relapse rates.
  • Existing treatments target dopamine pathways for positive symptoms but are insufficient for negative and cognitive symptoms.

Purpose of the Study:

  • To review the current treatment landscape for schizophrenia.
  • To identify the limitations of existing antipsychotic medications.
  • To emphasize the need for novel therapeutic strategies addressing all symptom domains.

Main Methods:

  • Literature review of schizophrenia pathophysiology and treatment efficacy.
  • Analysis of current antipsychotic mechanisms of action.
  • Evaluation of long-term patient outcomes and symptom persistence.

Main Results:

  • Antipsychotics effectively manage positive symptoms of schizophrenia by targeting dopamine pathways.
  • Less than 20% of first-episode patients maintain recovery long-term.
  • Negative and cognitive symptoms remain largely unaddressed by current therapies.

Conclusions:

  • Current antipsychotic treatments offer incomplete management of schizophrenia.
  • There is a critical unmet need for treatments that address the full spectrum of schizophrenia symptoms.
  • Future research should focus on developing comprehensive therapeutic approaches for schizophrenia.